# FLT PET in patienten met niet kleincellig long carcinoom behandeld met gefitinib.

No registrations found.

**Ethical review** Positive opinion **Status** Recruitment stopped

Health condition type -

**Study type** Observational non invasive

## **Summary**

#### ID

NL-OMON24060

Source

Nationaal Trial Register

**Health condition** 

**NSCLC** 

## **Sponsors and support**

**Primary sponsor:** VU University Medical Center (VUmc) Amsterdam

Source(s) of monetary or material Support: IMI

#### Intervention

#### **Outcome measures**

#### **Primary outcome**

The study parameters are the results of the simplified measures and the pharmacokinetic modeling of [18F]FLT PET prior to therapy and during treatment with gefitinib.

#### **Secondary outcome**

Secondary, nonlinear kinetic filtering will be evaluated and perfusion measured with [150]H2O PET.

# **Study description**

#### **Background summary**

The aim of the present study is to validate simplified quantitative methods for [18F]FLT PET in patients with non-small cell lung cancer (NSCLC) treated with gefitinib.

It is monocenter, prospective observational study including 10 patients with NSCLC who will be scanned with [150]H2O and [18F]FLT PET on three separate occasions: within 7 days prior to treatment, and 7 and 28 days after the first therapeutic dose of gefitinib, respectively. Full kinetic analysis will be performed.

#### Study objective

Simplified FLT PET parameter.

#### Study design

Baseline, and 7 and 28 days after start of treatment.

#### Intervention

[150]H2O and [18F]FLT PET scan at 3 different timepoints.

## **Contacts**

#### **Public**

Box 7057 O.S. Hoekstra Amsterdam 1007 MB The Netherlands

#### Scientific

Box 7057 O.S. Hoekstra Amsterdam 1007 MB The Netherlands

# **Eligibility criteria**

#### Inclusion criteria

- 1. Patient age 18 years or older;
- 2. Histological diagnosis of NSCLC;
- 3. Active EGFR-TK mutation;
- 4. Scheduled for treatment with gefitinib;
- 5. Tumour diameter > 3cm (to minimize partial volume effects) within the chest;
- 6. Able to remain supine for 90 minutes in the PET-CT scanner;
- 7. Written informed consent.

#### **Exclusion criteria**

- 1. Pregnant or lactating patients;
- 2. Metal implants (e.g. pacemakers);
- 3. Body weight > 100 kg.

# Study design

## **Design**

Study type: Observational non invasive

Intervention model: Parallel

Allocation: Non controlled trial

Masking: Open (masking not used)

Control: N/A, unknown

#### Recruitment

NL

Recruitment status: Recruitment stopped

Start date (anticipated): 01-09-2012

Enrollment: 10

Type: Actual

## **Ethics review**

Positive opinion

Date: 02-08-2012

Application type: First submission

# **Study registrations**

## Followed up by the following (possibly more current) registration

No registrations found.

### Other (possibly less up-to-date) registrations in this register

No registrations found.

## In other registers

Register ID

NTR-new NL3386 NTR-old NTR3557

Other METc VUmc: 12/172

ISRCTN wordt niet meer aangevraagd.

# **Study results**

#### **Summary results**

N/A